National and Kapodistrian University of Athens
Ο ρόλος των νευροτροφίνων NGF και BDNF στις γυναίκες με υπερδραστήρια κύστη και η συσχέτιση των επιπέδων τους με την κλινική εικόνα και την αποτελεσματικότητα της φαρμακευτικής θεραπείας
Abstract
dc:descriptionIntroduction-Purpose: Overactive Bladder Syndrome (OAB) is a condition with a prevalence of 16.9% that significantly affects patients' quality of life. Until now, the diagnosis of OAB and the assessment of the effectiveness of therapeutic methods have primarily relied on subjective tools. The purpose of this study is to evaluate the role of urinary neurotrophins NGF (Nerve Growth Factor) and BDNF (Brain-Derived Neurotrophic Factor) in patients with OAB undergoing treatment with Mirabegron, a β3-adrenergic agonist, as potential biomarkers to enhance the diagnosis of OAB and the evaluation of treatment effectiveness. Materials and Methods: The study included 30 patients diagnosed with OAB based on the definition of ICS (International Continence Society) and 15 healthy controls. Neurotrophin levels in urine were measured in samples collected at the beginning of the study (for both patients and controls) and three months after Mirabegron treatment (in the patient group). The determination was carried out using the Enzyme-Linked Immunosorbent Assay (ELISA) method, followed by further normalization of the values with urinary creatinine. The effectiveness of the treatment was assessed with the Indevus Urgency Severity Scale (IUSS) questionnaire. Results: Urinary NGF/Cre and BDNF/Cre levels were significantly higher in OAB patients compared to controls (p<0.001 and p=0.03, respectively). Additionally, NGF/Cre and BDNF/Cre levels significantly decreased after Mirabegron treatment in the entire patient group (p<0.001 and p=0.005, respectively); however, the decrease in the subgroup of women who did not respond to the treatment was not statistically significant (p=0.052 for NGF/Cre and p=0.878 for BDNF/Cre). Patients who responded to the treatment showed lower NGF/Cre levels three months post-treatment compared to those who did not respond (p=0.05).Conclusions: Patients with OAB exhibit increased urinary NGF and BDNF levels, which decrease after treatment. These findings suggest that NGF and BDNF might play a significant role in the development of overactive bladder symptoms and could emerge as potential biomarkers for assessing therapeutic outcomes. Using urinary NGF and BDNF measurements for diagnosing and evaluating OAB treatment could provide a more objective tool than existing patient-reported measures. Furthermore, understanding their role may offer insights into the pathophysiology of the syndrome and contribute to more targeted therapies in the future.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Beta, Anastasia
- Μπέτα, Αναστασία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57252